首页> 美国卫生研究院文献>other >ACTR-25. UPDATED RESULTS FROM A PROSPECTIVE RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE

【2h】

ACTR-25. UPDATED RESULTS FROM A PROSPECTIVE RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE

机译：ACTR-25。使用TVB-2640结合阿瓦斯汀对阿瓦斯汀单独治疗对重度星形胶质细胞瘤首发相关的患者进行前瞻性随机化的第2阶段研究的最新结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUNDStandard of care for glioblastoma multiforme (GBM) is surgical resection followed by temozolamide, with Avastin given at relapse. Responses to Avastin remain brief; resistance may involve overexpression of Fatty Acid Synthase (FASN). Our institution is conducting a phase 2 study of Avastin with or without the FASN inhibitor TVB-2640 in patients with GBM in first relapse.

机译：背景技术多形性胶质母细胞瘤（GBM）的护理标准是手术切除，然后进行替莫唑胺治疗，复发时给予Avastin。对Avastin的回复仍然简短；耐药可能涉及脂肪酸合酶（FASN）的过表达。我们的机构正在对首次复发的GBM患者中有或无FASN抑制剂TVB-2640的Avastin进行2期研究。

著录项

期刊名称 other
作者
Brandon Konkel; Laura Caflisch; Aldolfo Enrique Diaz Duque; Andrew J Brenner;
展开▼
作者单位

展开▼
年(卷),期 -1(20),Suppl 6
年度 -1
页码 vi16
总页数 1
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献

1. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study [J] . H. Hagberg, C. Gisselbrecht, and For the CORAL study group Annals of Oncology . 2006,第suppla4期

机译：R-ICE与R-DHAP在CD20弥漫性大B细胞淋巴瘤（DLBCL）复发患者中进行的III期随机研究，随后为大剂量治疗，以及是否随机给予利妥昔单抗维持治疗的第二次随机试验：CORAL研究的更新
2. Prospective, open-label, randomized, phase iii study of two dose-dense regimens MVAC versus gemcitabine/ cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: A hellenic cooperative oncology group study (HE 16/03) [J] . BamiasA., DafniU., KaradimouA., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第4期

机译：两种剂量密集方案MVAC与吉西他滨/顺铂在无法手术，转移性或复发性尿路上皮癌患者中进行的前瞻性，开放标签，随机，iii期研究，两种方法：希腊合作肿瘤小组研究（HE 16/03）
3. Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL [J] . Zelenetz Andrew D., Brown Jennifer R., Delgado Julio, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：艾达西单抗联合苯达莫司汀和利妥昔单抗治疗复发/难治性CLL患者的III期随机研究总生存率的最新分析
4. Computer-assisted, minimally invasive versus conventional knee arthroplasty: a prospective, randomized study [C] . Ng Y C, Dutton A Q, Yeo S J, International Society for Computer Assisted Orthopaedic Surgery. Meeting . 2007

机译：计算机辅助，微创与传统膝关节置换术：一项潜在的随机研究
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer [O] . J F Liu, W T Barry, M Birrer, -1

机译：西地那尼联合奥拉帕尼与奥拉帕尼联合治疗复发性铂敏感型卵巢癌的II期随机II期研究的总生存期和无进展生存期更新结果
7. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer [O] . J.F. Liu, W.T. Barry, M. Birrer, 2019

机译：在复发铂敏感的卵巢癌中，随机期II研究中的随机期II研究中的总存活和无进展的无进展生存结果在复发铂敏感的卵巢癌中的奥拉帕里

ACTR-25. UPDATED RESULTS FROM A PROSPECTIVE RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE

摘要

著录项

相似文献

相关主题

期刊订阅